Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Single vs Multi-fraction SRS Patients on Immunotherapy

Phase 2

Withdrawn

Conditions: Brain Cancer
Brain Metastases

Interventions: Radiation: Radiosurgery Single Treatment
Radiation: Radiosurgery Three Treatments

First Posted Date: 2020-06-11

Last Posted Date: 2023-08-28

Lead Sponsor: University of Chicago

Registration Number: NCT04427228

Locations: 🇺🇸
University Of Chicago, Chicago, Illinois, United States

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

Not Applicable

Completed

Conditions: HIV
Opioid-use Disorder
Hepatitis C
Injection Drug Use

Interventions: Behavioral: Referral to harm reduction services

First Posted Date: 2020-06-11

Last Posted Date: 2024-12-12

Lead Sponsor: University of Chicago

Target Recruit Count: 306

Registration Number: NCT04427202

Locations: 🇺🇸
Southern Illinois University, Carbondale, Illinois, United States
🇺🇸
The Community Action Place, Inc., Murphysboro, Illinois, United States

Virtual Teach-to-Goal Education vs. Brief Education for Children

Not Applicable

Completed

Conditions: Bronchospasm
Asthma
Shortness of Breath

Interventions: Behavioral: Brief Intervention
Behavioral: Virtual Teach to Goal

First Posted Date: 2020-05-04

Last Posted Date: 2021-04-29

Lead Sponsor: University of Chicago

Target Recruit Count: 70

Registration Number: NCT04373499

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

Phase 1

Recruiting

Conditions: Pancreatic Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Adenocarcinoma

Interventions: Drug: Oxaliplatin
Drug: Docetaxel
Drug: Leucovorin
Drug: Irinotecan
Drug: 5-Fluorouracil

First Posted Date: 2020-04-24

Last Posted Date: 2023-08-28

Lead Sponsor: University of Chicago

Target Recruit Count: 54

Registration Number: NCT04361708

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Leflunomide in Mild COVID-19 Patients

Phase 1

Terminated

Conditions: COVID-19

Interventions: Drug: Leflunomide

First Posted Date: 2020-04-24

Last Posted Date: 2024-02-07

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT04361214

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Long Term Outcomes of Patients With COVID-19

Active, not recruiting

Conditions: Corona Virus Infection
Covid-19
Critical Illness
Respiratory Failure

Interventions: Other: Quality of Life
Other: Impact Event Score
Other: Hospital anxiety and depression scale

First Posted Date: 2020-04-24

Last Posted Date: 2024-12-09

Lead Sponsor: University of Chicago

Target Recruit Count: 500

Registration Number: NCT04360538

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: Hydroxychloroquine

First Posted Date: 2020-04-17

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT04351620

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Low-dose Imaging Technique (LITE)

Not Applicable

Withdrawn

Conditions: Breast Cancer

Interventions: Diagnostic Test: Low-dose Imaging

First Posted Date: 2020-04-17

Last Posted Date: 2023-04-26

Lead Sponsor: University of Chicago

Registration Number: NCT04350957

Early Extubation for Patients With Acute Hypoxemic Respiratory Failure

Not Applicable

Withdrawn

Conditions: Mechanical Ventilation
Corona Virus Infection

Interventions: Device: Helmet non-invasive ventilation (NIV)

First Posted Date: 2020-04-16

Last Posted Date: 2024-05-02

Lead Sponsor: University of Chicago

Registration Number: NCT04349332

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

Early Phase 1

Completed

Conditions: Breast Fibroadenoma
Breast Neoplasms
Breast Diseases
Breast Cancer

First Posted Date: 2020-04-10

Last Posted Date: 2023-12-05

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT04341129

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy